Welcure Drugs & Pharmaceuticals Reports Q3FY26 Financial Results with Net Profit of ₹106.67 Lakhs

2 min read Updated on 12 Feb 2026, 08:10 PM

Reviewed by

Naman SScanX News Team

Overview

Welcure Drugs & Pharmaceuticals Limited reported Q3FY26 net profit of ₹106.67 lakhs on total income of ₹146.43 lakhs, with significant operational changes from previous quarters. The nine-month performance showed substantial growth with net profit of ₹4340.27 lakhs compared to ₹95.56 lakhs in the corresponding previous period. The company's paid-up equity capital increased to ₹12359.40 lakhs, indicating major capital restructuring during the quarter.

*this image is generated using AI for illustrative purposes only.

Welcure Drugs & Pharmaceuticals Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, showcasing notable operational performance during the period. The company's Board of Directors approved these results during their meeting held on February 12, 2026, at the registered office in New Delhi.

Financial Performance Overview

The pharmaceutical company reported mixed quarterly results with significant operational shifts compared to previous periods. The financial metrics demonstrate the company's evolving business focus and operational adjustments.

Metric	Q3FY26	Q2FY26	Q3FY25
Total Income	₹146.43 lakhs	₹6562.40 lakhs	₹883.80 lakhs
Revenue from Operations	₹0 lakhs	₹6562.40 lakhs	₹883.80 lakhs
Other Income	₹146.43 lakhs	₹0 lakhs	₹0 lakhs
Net Profit	₹106.67 lakhs	₹850.50 lakhs	₹41.50 lakhs
Basic EPS	₹0.13	₹0.76	₹0.04

Nine-Month Performance Highlights

The company demonstrated strong cumulative performance for the nine months ended December 31, 2025, significantly outperforming the corresponding period in the previous year.

Parameter	9M FY26	9M FY25	Growth
Total Income	₹36700.26 lakhs	₹2455.00 lakhs	Substantial increase
Net Profit	₹4340.27 lakhs	₹95.56 lakhs	Strong growth
Basic EPS	₹0.36	₹0.16	Improved earnings

Segment-wise Analysis

The company operates in two primary business segments: Agriculture and Drugs & Pharmaceuticals. During Q3FY26, the agriculture segment contributed the entire revenue, while the pharmaceutical segment showed no activity.

Agriculture Segment Performance:

Q3FY26 revenue: ₹146.43 lakhs
Segment assets: ₹19522.94 lakhs
Operating results (EBITDA): ₹142.55 lakhs

Drugs & Pharmaceuticals Segment:

Q3FY26 revenue: ₹0 lakhs
Previous quarter activity showed strong performance in pharmaceutical operations

Operational Metrics and Capital Structure

The company's paid-up equity share capital increased significantly to ₹12359.40 lakhs in Q3FY26 from ₹1125.12 lakhs in the previous quarter, indicating substantial capital restructuring. Total expenses for the quarter were ₹3.88 lakhs, primarily comprising employee benefits expense of ₹1.94 lakhs and other expenses of ₹1.44 lakhs.

Auditor's Review and Compliance

The financial results underwent limited review by statutory auditors Sarang Shivajirao Chavan and Associates, Chartered Accountants. The auditors issued their review report in accordance with Standard on Review Engagements (SRE) 2410, confirming compliance with Indian Accounting Standards and SEBI listing regulations.

The results were prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015, and comply with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Source:

Historical Stock Returns for Welcure Drugs & Pharmaceuticals